araag2/HINT huggingface dataset:
Clinical trial NCT00656175 (phase 2, status: completed)
Conditions: hiv infections, lipodystrophy
ICD codes: Z21, E88.1
Drugs: raltegravir
SMILES: CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western
             blot at any time prior to study entry or plasma HIV-1 RNA > 2000 on two occasions,

          -  Female subjects 18 years or older

          -  Documented central fat accumulation (defined by waist circumference of > 94 cm or a
             waist to hip ratio of > 0.88).

          -  Documented HIV RNA <50 copies/mL at screening and <400 copies/mL in the past 6 months.

          -  Current antiretroviral therapy with two nucleoside analogues and either a
             non-nucleoside analogue (nevirapine, efavirenz or TMC125) or an approved protease
             inhibitor. Patients on NNRTI+PI at study entry will be excluded. Study participants do
             not need to be on their first regimen. No changes in ART in the 12 weeks prior to
             screening. The nucleoside backbone must include either tenofovir or abacavir and
             either lamivudine or emtricitabine. Fixed dose combinations with emtricitabine or
             abacavir are allowed.

          -  For females of reproductive potential (women who have not been post-menopausal for at
             least 24 consecutive months, i.e., who have had menses within the preceding 24 months,
             or women who have not undergone surgical sterilization, specifically hysterectomy, or
             bilateral oophorectomy and/or tubal ligation), will need a negative serum or urine
             pregnancy test within 48 hours prior to entry.

          -  Ability and willingness of subject to provide informed consent.

        Exclusion Criteria:

          -  Pregnancy: current or within the past 6 months or breast feeding

          -  Prior treatment history that would preclude the use of emtricitabine or abacavir as
             the nucleoside backbone during study treatment

          -  Current use of metformin or thiazolidinediones.

          -  Use of growth hormone or growth hormone releasing factor in the last 6 months before
             screening.

          -  Change or initiation of anti-hyperlipemic regimen within 3 months prior to
             randomization; Use of stable anti-hyperlipemic regimen during the study is allowed.

          -  Current use of androgen therapy.

          -  Intent to modify diet, exercise habits or to enroll in a weight loss intervention
             during the study period.

          -  Current or projected need to use rifampin, dilantin or phenobarbital during the
             48-week study period.

          -  Laboratory values at screening of

               -  ANC >500 cells/mm3

               -  Hemoglobin <10 gm/dl

               -  CrCl > 60 ml/min (estimated by Cockcroft-Gault equation)

               -  AST or ALT > 3 x ULN
Clinical trial NCT00431340 (phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: pxd101
SMILES: ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1
Reason stopped: 
    terminated due to dose limiting toxicity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of multiple myeloma.

          -  Status of refractory to or relapsed from at least one prior bortezomib-containing
             regimen.

          -  Progressive disease.

          -  Age >= 18 years.

          -  Karnofsky performance status >= 60%

          -  Acceptable liver function:

               -  Bilirubin =< 1.5 x ULN (upper limit of normal)

               -  Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN

          -  Acceptable hematologic status:

               -  Absolute Neutrophil Count (ANC) >= 1.5 x 109/L

               -  Platelet count >= 100 x 109/L

               -  Hemoglobin >= 9 g/dL

               -  Coagulation status PT-INR/PTT =< 1.5 x ULN or in the therapeutic range if on
                  anticoagulation therapy. (PT-INR/PTT= prothrombin - international normalized
                  ratio / prothrombin time)

               -  Serum potassium within normal range.

          -  Estimated life expectancy greater than 3 months.

          -  Signed, written IRB (institutional Review Board)-approved informed consent.

        Exclusion Criteria:

          -  Non-secretory multiple myeloma or symptomatic amyloidosis.

          -  Hypersensitivity to bortezomib, boron, or mannitol.

          -  Less than 4 weeks since prior chemotherapy, radiotherapy, endocrine therapy, or
             immunotherapy, except if disease is rapidly progressing.

          -  Less than 4 weeks since prior use of other investigational agents.

          -  Serious concomitant systemic disorders (e.g. active infection).

          -  Significant cardiovascular disease.

          -  Marked baseline prolongation of QT/QTc (corrected QT interval)interval.

          -  Central nervous system disorders requiring neuroleptics / anti-convulsants.

          -  Peripheral sensory neuropathy of ≥ Grade 2

          -  Renal insufficiency defined as a creatinine clearance of < 30 ml/min.

          -  Non-willingness to use effective contraceptive methods for patients of child-bearing
             age / potential.

          -  Pregnant or breast-feeding women.

          -  Known HIV positivity.

          -  Prior treatment with belinostat (PXD101), or any other HDAC (histone deacetylase)
             inhibitor.

          -  Altered mental status which precludes an understanding of the Informed Consent
             Document.
Clinical trial NCT00583830 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: paclitaxel, carboplatin
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed stage IIIB or stage IV
             advanced primary non-small cell lung cancinoma

          -  Age 18 years or older

        Exclusion Criteria:

          -  Received investigational (not yet approved by a regulatory authority) or
             non-investigational agent to treat Lung Cancer

          -  Received radiation therapy within 4 weeks before randomization

          -  Major surgery within 4 weeks before randomization

          -  Minor surgery within 2 weeks before randomizaiton

          -  Systemic steroids within 1 week before randomization

          -  Any grade 2 or greater neuropathy

          -  History of severe (Grade 4) hypersensitivity reaction to products containing Cremophor
             EL (cyclosporine, teniposide)

          -  History of any infection requiring hospitalization or antibiotics within 2 weeks
             before randomization

          -  Known brain or spinal cord metastases

          -  History of other cancers within 5 years before randomization

          -  Known HIV, hepatitis-B or hepatitis-C infection

          -  Pregnant or breast-feeding women

          -  Previously treated with Mapatumumab
Clinical trial NCT01227681 (phase 2, status: terminated)
Conditions: parkinson disease
ICD codes: G20
Drugs: g-csf, placebo
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    difficulty in recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Hoehn & Yahr stage I~III

          -  Patients with idiopathic Parkinson's disease(PD), who meet the United Kingdom
             Parkinson's Disease Society Brain Bank diagnostic criteria, with a good response to
             levodopa

          -  The onset of PD symptoms must be occurred > = 40 years of age (to exclude YOPD), and
             the patient must have been diagnosed with idiopathic PD > =40 years of age

          -  Patients may have symptoms of wearing OFF and/or levodopa induced dyskinesia

          -  Patients must rate between Hoehn & Yahr stage I to III, when in an OFF medication
             state

          -  Patients must in their optimal medication treatment state, and will not changing their
             medications within 3 months before and after enrollment

        Exclusion Criteria:

          -  Patients who are proved to be Young Onset Parkinson's Disease (YOPD) and/or
             genetically related (e.g. Parkin).

          -  Women of child-bearing potential, pregnant or lactating.

          -  Patients who are proved to have tumor growth and/or malignancy.

          -  Patients with a past (within one year) or present history of psychotic symptoms
             requiring anti- psychotic treatment.

          -  Patients with active symptoms of major depression with suicidal ideation or suicide
             attempt.

          -  Patients with previous brain surgery (including pallidotomy and deep brain
             stimulation).

          -  Patients with significant cognitive impairment ( Mini-Mental State Examination, MMSE <
             24).

          -  Patients who do not sign the inform consent,
Clinical trial NCT01290718 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: capecitabine [xeloda], trastuzumab [herceptin]
SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients, 18-65 years of age

          -  Histologically confirmed HER2-positive breast cancer with measurable lesions
             (according to RECIST criteria)

          -  Metastatic disease after first-line therapy or recurrent disease after (neo)adjuvant
             therapy with Herceptin and taxanes

          -  ECOG performance status 0-2

        Exclusion Criteria:

          -  CNS metastases which are not well controlled

          -  Simultaneous treatment with sorivudine

          -  History of another malignancy within the last 5 years except for cured basal cell
             carcinoma of the skin and cured carcinoma in-situ of the uterine cervix

          -  Pregnant or lactating women
Clinical trial NCT01175135 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: pf-02545920, pf-02545920, placebo, risperidone
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of schizophrenia with acute exacerbation of illness

          -  The current acute exacerbation of schizophrenia must be less than 4 weeks duration
             prior to the initial evaluation.

        Exclusion Criteria:

          -  Subjects with evidence or history of clinically significant uncontrolled medical
             illness

          -  Subjects with a current diagnosis of schizoaffective disorder, major depression,
             bipolar disorder, or obsessive compulsive disorder.

          -  Subjects who meet Diagnostic and Statistical Manual-IV (DSM-IV)defined diagnostic
             criteria for psychoactive substance dependence (excluding nicotine dependence) within
             12 months of screening or DSM-IV defined substance abuse within 3 months prior to
             screening.
Clinical trial NCT00855114 (phase 2, status: withdrawn)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: everolimus
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    withdrawn due to no accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of invasive breast cancer

               -  Resectable disease

          -  Measurable disease, defined as a primary breast mass > 2.0 cm by breast imaging or
             clinical exam

          -  Planning to undergo surgical resection after neoadjuvant therapy

          -  Menopausal status not specified

          -  Eastern Clinical Oncology Group (ECOG) performance status 0-1

          -  Absolute neutrophil count (ANC) ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin > 9.0 g/dL

          -  Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 2.5 times upper limit
             of normal (ULN)

          -  Creatinine ≤ 1.5 times ULN

          -  Total bilirubin ≤ 1.5 times ULN

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        Exclusion Criteria:

          -  Intracranial disease

          -  Hormone receptor status not specified

          -  Obese (> 250 pounds)

          -  Immunosuppression from any cause (e.g., known HIV infection)

          -  History of severe asthma and/or allergies

          -  History of severe claustrophobia

          -  Ferromagnetic implants, history of shotgun wound and/or shrapnel, cardiac pacemakers,
             or other similar situations that would be contrary to strong magnetic force

          -  Bleeding diathesis

          -  Unstable systemic disease, including but not limited to, any of the following:

               -  Uncontrolled diabetes

               -  Severe infection

               -  Severe malnutrition

               -  Uncontrolled hypertension

               -  Unstable angina

               -  Ventricular arrhythmias

               -  Active ischemic heart disease

               -  Congestive heart failure

               -  Myocardial infarction within the past 6 months

               -  Chronic liver disease

               -  Renal disease

               -  Active upper gastrointestinal tract ulceration

          -  Less than 4 weeks since prior investigational drug

          -  Prior therapy with sirolimus or its analogues

          -  Concurrent immunosuppressive therapy (e.g., steroids, cytotoxic agents, or concurrent
             radiotherapy)

          -  Concurrent anticoagulation (i.e., coumadin)
Clinical trial NCT00385580 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: dasatinib, dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  males, 18 or older

          -  proven advanced prostate cancer

          -  documented metastatic disease

          -  rising PSA levels

          -  castrate levels of testosterone

        Exclusion Criteria:

          -  symptomatic CNS (brain or spinal cord) metastasis

          -  medical condition which may increase the risk of toxicity

          -  any prior or ongoing anti-cancer medical therapy or immunotherapy for prostate cancer
             other than primary androgen deprivation agents

          -  unable to take oral medication
Clinical trial NCT01071850 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ipragliflozin, metformin, placebo
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has been diagnosed with type 2 diabetes

          -  Subject has a HbA1c value between 6.8 and 9.5%

          -  Subject has never, is not currently taking anti-diabetic medication OR is receiving a
             single anti- diabetic agent or low-doses two anti-diabetic medications and is willing
             to discontinue them during the study

          -  Subject is on a stable diet and exercise program

          -  Female subject is not pregnant and agrees to use an acceptable form of contraception
             throughout the duration of the study

        Exclusion Criteria:

          -  Subject has type 1 diabetes mellitus

          -  Subject is using insulin therapy

          -  Subject has a serum creatinine higher than upper limit of normal

          -  Subject has an ALT and/or AST value higher than 3 times upper limit of normal or a
             total bilirubin value more than 2 times upper limit of normal

          -  Subject has persistent, uncontrolled severe hypertension as indicated by a

        systolic blood pressure >180 mmHg or a diastolic blood pressure of

        >110mmHg

          -  Subject has had significant cardiovascular disease such as myocardial infarction or a
             vascular intervention (e.g., angioplasty or stent) in the last 3 months

          -  Subject is known to have hepatitis or be a carrier of hepatitis B surface

        antigen, hepatitis C virus antibody or is known positive for HIV1 and/or

        HIV2

          -  Subject has a history of lactic acidosis

          -  Subject has a history of drug and alcohol abuse/dependency within last 12

        months

          -  Subject has had a malignancy in the last 5 years, except for successfully

        treated basal or squamous cell carcinoma of the skin or of the cervix

          -  Subject has a symptomatic urinary tract infection or genital infection

          -  Female subject is lactating

          -  Subject has an unstable medical or psychiatric illness
Clinical trial NCT00419159 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: everolimus (rad001)
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion criteria:

          -  Age ≥ 18 years old.

          -  Patients with metastatic colorectal cancer (CRC).

          -  Patients must have sufficient and obtainable tumor tissue for biomarker analysis from
             original surgical resection.

          -  Patients with documented disease progression within 6 months of their most recent dose
             of chemotherapeutic regimens.

          -  Patients with at least one measurable lesion.

          -  Adequate bone marrow function.

          -  Adequate liver function.

          -  Adequate renal function.

          -  Patients with a life expectancy of > 3 months.

          -  Patients with a World Health Organization (WHO) performance status of 0, 1, or 2.

          -  Women of childbearing potential must have had a negative serum pregnancy test 72 hours
             prior to the administration of the first study treatment.

          -  Patients who give a written informed consent obtained according to local guidelines.

        Exclusion criteria:

          -  Patients currently receiving anti-cancer agents or who have received these within 4
             weeks prior to study entry.

          -  Patients who have previously received RAD001.

          -  Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus,
             temsirolimus) or to its excipients.

          -  Chronic treatment with steroids or another immunosuppressive agent.

          -  Patients with untreated central nervous system (CNS) metastases or neurologically
             unstable CNS metastases.

          -  HIV seropositivity.

          -  Patients with an active, bleeding diathesis. Patients may use enoxaparin.

          -  Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study.

          -  Patients who have a history of another primary malignancy < 3 years, with the
             exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix.

          -  Female patients who are pregnant or breast feeding, or adults of reproductive
             potential who are not using effective birth control methods.

          -  Patients who are using other investigational agents or who had received
             investigational drugs ≤ 4 weeks prior to first study treatment.

          -  Patients unwilling to or unable to comply with the protocol.

        Other protocol defined inclusion/exclusion criteria may apply
Clinical trial NCT00809185 (phase 2, status: terminated)
Conditions: myelodysplastic syndromes
ICD codes: D46.9, D46.C, D46.Z
Drugs: everolimus
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Low or intermediate-1 risk myelodysplastic syndromes by International Prognostic
             Scoring System (IPSS) criteria

               -  IPSS score < 1.5

          -  Requiring transfusion of 2 units of red blood cells at least once a month (four weeks
             prior to accrual on study)

          -  High levels of endogenous epoetin alfa (i.e., > 200 mU/mL)

               -  Unlikely to respond to epoetin alfa, or has a documented clinical non-response to
                  epoetin alfa (at a dose of ≥ 40,000 U weekly) or darbepoetin alfa (at a dose >
                  200 mcg every other week) (i.e., < 2 g/dL increase in hemoglobin and no decrease
                  in transfusion requirements after at least 4 weeks of treatment)

          -  No chronic myelomonocytic leukemia

        PATIENT CHARACTERISTICS:

          -  ECOG Performance Status of 0-2

          -  Liver enzymes (AST and ALT) and total bilirubin ≤ 2 times upper limit of normal

          -  Serum creatinine ≤ 2 times upper limits of normal

          -  No clinically significant anemia due to iron, B12, or folate deficiencies; autoimmune
             or hereditary hemolysis; or gastrointestinal bleeding

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other serious or poorly controlled medical condition that could be exacerbated by
             or complicate compliance with study therapy

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior treatment (including growth factors)

          -  No chronic use (> 2 weeks) of physiologic doses of a corticosteroid agent (dose
             equivalent to > 10 mg/day of prednisone) within 28 days of the first day of study drug

          -  No concurrent use of another investigational agent

          -  No concurrent therapy with any cytotoxic drugs, steroids, or growth factors
Clinical trial NCT01070524 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: chf 5188 pmdi, budesonide extrafine pmdi, seretide(r) evohaler(r)
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Moderate or severe asthma partly controlled with ICS or ICS/LABA

          -  FEV1 ≥ 60% and ≤ 90% of predicted for the patient normal value

        Exclusion Criteria:

          -  Diagnosis of COPD

          -  History or current evidence of significant cardiovascular disease

          -  Uncontrolled concomitant disease